PL2989114T3 - Pochodne 2,2-difluoropropionamidowe metylu bardoksolonu, polimorficzne postacie i sposoby ich zastosowania - Google Patents

Pochodne 2,2-difluoropropionamidowe metylu bardoksolonu, polimorficzne postacie i sposoby ich zastosowania

Info

Publication number
PL2989114T3
PL2989114T3 PL14727306T PL14727306T PL2989114T3 PL 2989114 T3 PL2989114 T3 PL 2989114T3 PL 14727306 T PL14727306 T PL 14727306T PL 14727306 T PL14727306 T PL 14727306T PL 2989114 T3 PL2989114 T3 PL 2989114T3
Authority
PL
Poland
Prior art keywords
methods
polymorphic forms
bardoxolone methyl
difluoropropionamide
derivatives
Prior art date
Application number
PL14727306T
Other languages
English (en)
Inventor
Ahmad Y. Sheikh
Alessandra MATTEI
Xiu C. Wang
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of PL2989114T3 publication Critical patent/PL2989114T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PL14727306T 2013-04-24 2014-04-24 Pochodne 2,2-difluoropropionamidowe metylu bardoksolonu, polimorficzne postacie i sposoby ich zastosowania PL2989114T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815502P 2013-04-24 2013-04-24
PCT/US2014/035279 WO2014176415A1 (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
EP14727306.4A EP2989114B1 (en) 2013-04-24 2014-04-24 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2989114T3 true PL2989114T3 (pl) 2018-10-31

Family

ID=50842351

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14727306T PL2989114T3 (pl) 2013-04-24 2014-04-24 Pochodne 2,2-difluoropropionamidowe metylu bardoksolonu, polimorficzne postacie i sposoby ich zastosowania

Country Status (35)

Country Link
US (5) US9856286B2 (pl)
EP (2) EP3453715A1 (pl)
JP (2) JP6409050B2 (pl)
KR (2) KR102342915B1 (pl)
CN (1) CN105324389B (pl)
AR (1) AR096046A1 (pl)
AU (2) AU2014257072C1 (pl)
BR (1) BR112015027012B1 (pl)
CA (1) CA2909066C (pl)
CL (1) CL2015003135A1 (pl)
CR (1) CR20150620A (pl)
CY (1) CY1120570T1 (pl)
DK (1) DK2989114T3 (pl)
DO (1) DOP2015000263A (pl)
EC (1) ECSP23088864A (pl)
ES (1) ES2683626T3 (pl)
HR (1) HRP20181321T1 (pl)
HU (1) HUE039899T2 (pl)
IL (1) IL242183B (pl)
LT (1) LT2989114T (pl)
MX (1) MX372760B (pl)
MY (1) MY182677A (pl)
PE (1) PE20160006A1 (pl)
PH (1) PH12015502459B1 (pl)
PL (1) PL2989114T3 (pl)
PT (1) PT2989114T (pl)
RS (1) RS57571B1 (pl)
RU (2) RU2019120236A (pl)
SG (2) SG11201508752WA (pl)
SI (1) SI2989114T1 (pl)
TW (2) TWI649330B (pl)
UA (1) UA118348C2 (pl)
UY (2) UY35534A (pl)
WO (1) WO2014176415A1 (pl)
ZA (1) ZA201507481B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022166B1 (ru) 2008-01-11 2015-11-30 Ритэ Фамэсутиклс, Инк. Синтетические тритерпеноиды и их применение в лечении заболеваний
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
MX2010011438A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Antioxidantes moduladores de la inflamacion: derivados del acido oleanólico con amino y otras modificaciones en c-17.
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
CA2988593C (en) 2015-06-16 2023-10-24 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN106279344A (zh) * 2016-08-14 2017-01-04 吴芊葭 一种从防风中分离的天然化合物及其制备方法、医药应用
CN106309451A (zh) * 2016-08-14 2017-01-11 吴芊葭 一种头孢呋辛酯的药物组合物及其医药用途
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20190388407A1 (en) 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
CN108558985B (zh) * 2018-05-19 2019-06-07 河南省科学院高新技术研究中心 白桦脂酸衍生物及其合成方法和应用
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
EP3836927A4 (en) 2018-08-15 2022-05-11 AiViva Biopharma, Inc. MULTIKINASE INHIBITORS OF VEGF AND TGF-BETA AND THEIR USES
UA126950C2 (uk) 2018-08-20 2023-02-22 Янссен Фармацевтика Нв Інгібітори міжбілкової взаємодії keap1-nrf2
US20200323882A1 (en) * 2019-03-15 2020-10-15 University Of Rhode Island Board Of Trustees Phlip®-mediated targeting of corticosteroids to diseased tissue
WO2020226201A1 (ko) * 2019-05-08 2020-11-12 경상대학교병원 피부 저색소증 예방 또는 치료용 약학적 조성물, 건강기능식품 및 화장료 조성물
TWI861163B (zh) 2019-07-19 2024-11-11 美商瑞塔醫藥有限責任公司 C17經極性取代之雜芳合成三萜類化合物及其使用方法
WO2021127480A1 (en) * 2019-12-19 2021-06-24 Reata Pharmaceuticals, Inc. Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
EP4259155A1 (en) * 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
MX2023008454A (es) * 2021-01-18 2023-08-07 Reata Pharmaceuticals Inc Derivados sintéticos de ácido ursólico y métodos de uso de estos.
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
MX2024008480A (es) 2022-01-07 2024-07-15 Chugai Pharmaceutical Co Ltd Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2).
EP4349847A1 (en) * 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof
CN121152792A (zh) 2023-06-19 2025-12-16 中外制药株式会社 具有Nrf2活化作用的含氮杂环化合物的晶体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
MXPA04006953A (es) 2002-01-18 2005-06-20 Univ Minnesota Sales cuaternarias de triperpeno como surfactantes biologicamente activos.
WO2004064723A2 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
AU2006265113A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン(tbe)の合成および生物学的活性
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
EA022166B1 (ru) 2008-01-11 2015-11-30 Ритэ Фамэсутиклс, Инк. Синтетические тритерпеноиды и их применение в лечении заболеваний
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ES2613964T3 (es) 2008-04-18 2017-05-29 Reata Pharmaceuticals, Inc. Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17
MX2010011438A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Antioxidantes moduladores de la inflamacion: derivados del acido oleanólico con amino y otras modificaciones en c-17.
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
SI3254675T1 (sl) 2009-02-13 2019-08-30 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
EP2432476A4 (en) 2009-05-01 2013-03-20 Ophthotech Corp METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
JP5857068B2 (ja) 2010-12-17 2016-02-10 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン
AU2012229244B2 (en) * 2011-03-11 2017-05-25 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CA2882417C (en) 2012-09-10 2021-04-20 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
AU2014308600B2 (en) 2013-08-23 2020-03-05 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US9464082B2 (en) 2014-01-24 2016-10-11 Abbvie Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
NZ741082A (en) 2015-09-23 2023-06-30 Reata Pharmaceuticals Inc C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
IL242183B (en) 2019-10-31
UY35534A (es) 2014-10-31
SG11201508752WA (en) 2015-11-27
JP2019023200A (ja) 2019-02-14
RU2015150069A3 (pl) 2018-03-21
US11873320B2 (en) 2024-01-16
KR102342915B1 (ko) 2021-12-24
US20240228528A1 (en) 2024-07-11
CN105324389B (zh) 2018-02-06
US20200062800A1 (en) 2020-02-27
AU2014257072C1 (en) 2020-07-16
JP6409050B2 (ja) 2018-10-17
KR20210018555A (ko) 2021-02-17
EP2989114B1 (en) 2018-05-23
CA2909066A1 (en) 2014-10-30
ECSP23088864A (es) 2023-12-29
AU2019200341A1 (en) 2019-02-07
HUE039899T2 (hu) 2019-02-28
CL2015003135A1 (es) 2016-06-10
US20140323579A1 (en) 2014-10-30
LT2989114T (lt) 2018-08-10
NZ749873A (en) 2020-09-25
MX2015014792A (es) 2016-03-07
DK2989114T3 (en) 2018-08-20
PT2989114T (pt) 2018-10-10
WO2014176415A1 (en) 2014-10-30
RU2015150069A (ru) 2017-05-29
UA118348C2 (uk) 2019-01-10
US12384815B2 (en) 2025-08-12
RU2693833C2 (ru) 2019-07-05
ES2683626T3 (es) 2018-09-27
TW201518314A (zh) 2015-05-16
PH12015502459B1 (en) 2020-11-18
HK1221470A1 (zh) 2017-06-02
TWI649330B (zh) 2019-02-01
US20180094020A1 (en) 2018-04-05
AU2014257072A1 (en) 2015-10-29
AU2014257072B2 (en) 2018-10-18
PH12015502459A1 (en) 2016-02-22
UY39092A (es) 2021-03-26
EP2989114A1 (en) 2016-03-02
ZA201507481B (en) 2021-05-26
RS57571B1 (sr) 2018-11-30
CY1120570T1 (el) 2019-07-10
MX372760B (es) 2020-06-29
DOP2015000263A (es) 2015-12-15
BR112015027012A2 (pt) 2017-07-25
BR112015027012B1 (pt) 2023-01-10
JP2016517869A (ja) 2016-06-20
US20220073559A1 (en) 2022-03-10
RU2019120236A3 (pl) 2019-12-04
EP3453715A1 (en) 2019-03-13
SI2989114T1 (sl) 2018-09-28
SG10201805231WA (en) 2018-08-30
RU2019120236A (ru) 2019-07-22
US9856286B2 (en) 2018-01-02
TW201936625A (zh) 2019-09-16
KR20150144807A (ko) 2015-12-28
CR20150620A (es) 2016-01-12
US11117927B2 (en) 2021-09-14
HRP20181321T1 (hr) 2018-10-19
CN105324389A (zh) 2016-02-10
HK1222179A1 (en) 2017-06-23
MY182677A (en) 2021-01-29
CA2909066C (en) 2021-08-03
AR096046A1 (es) 2015-12-02
PE20160006A1 (es) 2016-02-03

Similar Documents

Publication Publication Date Title
IL242183B (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of their use
HUS2400010I1 (hu) Bardoxolon metil 2,2-difluorpropionamid-származékai, azok polimorf formái és eljárások alkalmazásaikra
ZA201601737B (en) Processes for preparing dihydropyrimidine derivatives and intermediates thereof
IL240475B (en) Tubulin compounds, methods for their preparation and use
EP2968307A4 (en) Carboxamide derivatives and use thereof
IL244268A0 (en) Heterocyclic compounds and methods of use
ZA201604502B (en) Use of benzimidazole-proline derivatives
IL244214B (en) Thienopiperidine derivative and its use
IL246059A0 (en) Polymorphic and amphoteric forms of cortisol 17-alpha-benzoate and methods for their preparation and use
SG11201509920UA (en) Polymorphic forms of icotinib and uses thereof
GB201412023D0 (en) Method of producting derivatives of 1,3,5-triarylbenzene and truxene